Bayer (FRA:BAYN) has been given a €88.50 ($102.91) target price by investment analysts at Warburg Research in a research note issued on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Warburg Research’s target price points to a potential upside of 12.93% from the company’s current price.

Several other analysts also recently weighed in on BAYN. Sanford C. Bernstein set a €118.00 ($137.21) price target on shares of Bayer and gave the company a “buy” rating in a research note on Thursday, June 14th. Jefferies Financial Group set a €120.00 ($139.53) price target on shares of Bayer and gave the company a “buy” rating in a research note on Friday, June 15th. Citigroup set a €132.00 ($153.49) price target on shares of Bayer and gave the company a “buy” rating in a research note on Monday, June 18th. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a research note on Tuesday, June 19th. Finally, JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of Bayer and gave the company a “buy” rating in a research note on Thursday, June 21st. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Bayer currently has a consensus rating of “Buy” and a consensus target price of €98.80 ($114.88).

Bayer stock opened at €78.37 ($91.13) on Thursday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: How is the discount rate different from the Federal Funds rate?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.